|
|
Advertisement |
 |
|
|
Lead Story |
|
The EU’s Conflicted Stance on Neglected Diseases |
The failures in developing treatments for neglected diseases is perceived as a demonstration of the failure of the development model that richer countries have depended on, and which may also prove deficient in the face of evolving challenges. Reflector reports /Read more/ |
|
|
Vaccines |
|
Anti-Vaccine Movement Rears Its Ugly Head Again |
Despite research by eminent scientists as to the safety and benefits of immunization for children and adults, the anti-vaccine film “Vaxxed: From Cover-Up to Catastrophe” has all the emotional elements to convince millions that vaccines are unsafe and dangerous, writes Jill Wechsler /Read more/ |
|
|
|
|
CEO Snapshot |
 |
LEO Pharma’s Dermatology Drive |
LEO Pharma CEO Gitte Aabo talks to PE about issues pertinent to the dermatology therapy area and how LEO’s unconventional business model is helping the company achieve its objectives /Read more/ |
|
|
Emerging Pharma Leaders |
 |
Pharm Exec’s Emerging Pharma Leaders 2016 — Nominate Now |
Pharm Exec is looking for the fresh faces of pharma leadership. And we’d like your input. Tell us who you think should be included as one of our 2016 Emerging Pharma Leaders. These leaders are vital to the future of the industry, and you can help ensure they get the recognition they deserve. Fill out your nomination today /Read more/ |
|
|
|
Industry update |
//GSK’s Sir Andrew Whitty announced that he will step down at the end of March 2017.//Cancer Research UK appointed Professor Alexander Eggermont, M.D., Ph.D, as a Trustee.//Kymab (Cambridge, UK) named Dr. David Chiswell as CEO.//Kuros Biosciences (Zurich, Switzerland) appointed Dr. Virginia Jamieson as Chief Medical Officer and member of the Executive Board.// |
|
|
|
|